关于多发性硬化症患者认知功能障碍的治疗和管理的最新情况
Ermelinda De Meo1,2, Emilio Portaccio1, Raffaello Bonacchi3
1NEUROFARBA, University of Florence, Florence, Italy.
Expert review of neurotherapeutics
|January 13, 2025
概括
认知障碍影响许多多发性硬化症 (MS) 患者,影响生活质量. 管理需要一个多方面的方法,包括康复和炼,以提高认知能力.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
- 康复医学 康复医学 康复医学
背景情况:
- 认知障碍 (CI) 影响34-70%的多发性硬化症 (MS) 患者,无论身体残疾.
- 通常受影响的认知领域包括处理速度,记忆和执行功能.
研究的目的:
- 审查目前对多发性硬化症认知障碍的理解和管理策略.
- 确定MS认知康复未来研究的关键领域.
主要方法:
- 在PubMed和Google学者的综合文献搜索.
- 关键词:"MS"",认知"",认知康复".
- 专注于临床评估,认知表型和治疗选择.
主要成果:
- 在MS的认知缺陷是异质的,但经常涉及处理速度,记忆和执行功能.
- 有一系列的药物和非药物治疗方法,包括疾病修饰疗法和认知康复.
结论:
- 在MS中管理CI时,必须采取多方面的方法,整合药理疗法,认知康复和运动.
- 未来的研究应该集中在最佳培训,持续的认知增强和临床试验中的生物标志物上.
相关概念视频
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Parkinson's Disease: Treatment
206
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
206
Alzheimer's Disease: Overview
440
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
440
Cognitive Development During Adulthood
49
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
49
Parkinson's Disease: Overview
463
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
463


